companyprofile

Actions

Jamjoom Pharmaceuticals Factory Co.

4015
JAMJOOM PHARMA
Add To Watchlist
In your Watchlist
Add To Watchlist
  • Main Market
  • Pharma, Biotech & Life Science

Stats Overview

  • Prev. Close 129.40
  • Open 129.00
  • High 131.20
  • Low 127.80
  • No. of Trades 1,363
  • Avg. Trade size* 104
  • Volume Traded 141,647
  • Value Traded (SAR) 18,392,769.60

Performance

JAMJOOM PHARMA
0.60 ( 0.46% )
View Historical
Compare
Name Price Change %
Jamjoom Pharmaceuticals Factory Co. 129.00 0.46%
Note: Prices are delayed minimum 5 minutes
  • *Average Trade Size = Cumulative / # of Trades
  • **52 Week Price Change =   (Current Price - Price year ago) / Price year ago x 100
  • Historical prices & volume traded data are adjusted to account for all corporate actions.
  • MO: Market Order

Trade Updates

Last Trade

Price
130.00
% Change
0.46
Volume Traded
10

Best Bid

Price 129.80
Volume 1,641

Best Offer

Price 130.00
Volume 9,088

52 WEEK

High
158.20
2024/02/13
Low
66.00
2023/06/20
Change**
0.0

PERFORMANCE

Start of Year
114.6
Year ago
3 Years ago

Compare Selected

Select a Maximum of 5 Companies

Compare Selected

LoginPortletPopupv2

Actions

AddtoWatchlistv2

Actions

Add to watchlist

Apply Selected

AnnouncmentandCorporateAction

Actions
Jump To :
  • Announcements & Corporate Actions
  • Dividends
  • Financials
  • Shareholding
  • Peer Comparison
  • Company Profile

Announcements

  • Jamjoom Pharmaceuticals Factory Co. announces the board of director’s recommendation to distribute cash dividends for the second half of the year 2023.

    4015
    JAMJOOM PHARMA 0.46 %
    1445/09/25     04/04/2024 08:19:45

  • Jamjoom Pharmaceuticals Factory Co. announces its Annual Financial results for the period ending on 2023-12-31

    4015
    JAMJOOM PHARMA 0.46 %
    1445/09/15     25/03/2024 08:08:49

  • Jamjoom Pharmaceuticals Factory Co. announces its intention to release its annual financial results for the year ended 31 December 2023 on Monday, March 25, 2024, before the trading session begins on the Saudi Exchange

    4015
    JAMJOOM PHARMA 0.46 %
    1445/09/09     19/03/2024 08:04:52

  • Correction announcement from Jamjoom Pharmaceuticals Factory Co. in regards to its Announcement on the Results of the Extraordinary General Assembly Meeting (First Meeting)

    4015
    JAMJOOM PHARMA 0.46 %
    1445/09/04     14/03/2024 08:06:12

  • Jamjoom Pharmaceuticals Factory Co. Announces the Results of the Extraordinary General Assembly Meeting, ( First Meeting )

    4015
    JAMJOOM PHARMA 0.46 %
    1445/09/03     13/03/2024 08:14:15
View All

Corporate Actions

Upcoming Events

    Past Events

      Jump To :
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Dividends

      Announced Date Eligibility Date Distribution Date Distribution Way Dividend Amount
      04/04/2024 N/A N/A Account Transfer 1.50
      10/08/2023 20/08/2023 03/09/2023 Account Transfer 1.00

      CompanyProfilev2Financials

      Actions
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Financials

      • FINANCIAL INFORMATION
      • FINANCIAL STATEMENTS AND REPORTS
      • Annually
      • Quarterly
      Balance Sheet 2023-12-31
      Total Assets
      1,654,166
      		 - - -
      Total Liabilities
      249,837
      		 - - -
      Total Shareholders Equity (After Deducting the Minority Equity)
      1,404,329
      		 - - -
      Total Liabilities and Shareholders Equity
      1,654,166
      		 - - -
      Statement of Income 2023-12-31
      Total Revenue (Sales/Operating)
      1,100,819
      		 - - -
      Net Profit (Loss) before Zakat and Tax
      315,799
      		 - - -
      Zakat and Income Tax
      -23,399
      		 - - -
      Net Profit (Loss) after Zakat and Tax
      292,400
      		 - - -
      Total Comprehensive Income
      258,066
      		 - - -
      Profit (Loss) per Share
      4.18
      		 - - -
      Cash Flow 2023-12-31
      Net Cash From Operating Activities
      296,028
      		 - - -
      Net Cash From Investing Activities
      -77,442
      		 - - -
      Net Cash From Financing Activities
      -70,347
      		 - - -
      Cash and Cash Equivalents, Beginning of the Period
      141,182
      		 - - -
      Cash and Cash Equivalents, End of the Period
      284,277
      		 - - -
      All Figures in Thousands
      All Currency In SAR
      Last Update Date 2024-04-01

      The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.

      Balance Sheet 2023-09-30
      Total Assets
      1,658,857
      Total Liabilities
      297,559
      Total Shareholders Equity (After Deducting the Minority Equity)
      1,361,298
      Total Liabilities and Shareholders Equity
      1,658,857
      Statement of Income 2023-09-30
      Total Revenue (Sales/Operating)
      292,613
      Net Profit (Loss) before Zakat and Tax
      83,858
      Zakat and Income Tax
      -6,611
      Net Profit (Loss) after Zakat and Tax
      77,247
      Total Comprehensive Income
      76,433
      Profit (Loss) per Share
      1.1
      Cash Flow 2023-09-30
      Net Cash From Operating Activities
      95,843
      Net Cash From Investing Activities
      -68,686
      Net Cash From Financing Activities
      -70,263
      Cash and Cash Equivalents, Beginning of the Period
      141,182
      Cash and Cash Equivalents, End of the Period
      93,191
      All Figures in Thousands
      All Currency In SAR
      Last Update Date 2023-11-12

      The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.

      Display Previous Periods
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Shareholding Information

      • Board Of Directors
      • Foreign Ownership
      • Substantial Shareholders
      Time Period
      -
      Search
      Trading Date Shareholders Designation Shares Held Trading Day Shares Held Prev Trading Day Change
      2024-04-25 محمود يوسف محمدصلاح جمجوم Chairman 5.6000000% 5.6000000% 0
      2024-04-25 نور أحمد شريف Board of Directors 0.0728700% 0.0728700% 0
      2024-04-25 يوسف محمد صلا ح عبد العزيز جمجوم Board of Directors 41.6500000% 41.6500000% 0
      2024-04-25 احمد يوسف محمدصلاح جمجوم Board of Directors 4.5500000% 4.5500000% 0
      2024-04-25 الاء يوسف محمد جمجوم Board of Directors 4.5500000% 4.5500000% 0
      2024-04-25 محمد يوسف محمد صلاح جمجوم Board of Directors 4.5500000% 4.5500000% 0
      • The listed company (Publisher) shall be responsible for the accuracy of the published information pertaining to the ownership of the Board of Directors, Chief Executive Officer or highest executive position, and the Chief Financial Officer. The listed company shall also be responsible for updating these information thereof. Therefore, the Saudi Stock Exchange (Tadawul) shall not be liable for the information contained therein, nor for any consequences that may result from the said information.
      for
      subs
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Peer Comparison

      • Table
      • Graphical
      Add Company

      Compare Selected

      Select a Maximum of 5 Companies

      Company Apply
      Jamjoom Pharmaceuticals Factory Co.
      Price 130.00
      Market Cap (SAR MN) 9,226
      P/E Ratio 31.55
      Index Name Index Level 1D Return
      Jamjoom Pharmaceuticals Factory Co. %
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Company Profile

      Company overview

      The Company is primarily focused on developing, manufacturing, and distributing a wide range of generic pharmaceuticals, cosmetics, and consumer healthcare products. Its products are supplied and marketed in over 36 countries spanning across the GCC, Levant, North Africa, and other regions, the company is committed to providing high-quality products to its customers. Its extensive portfolio of offerings and its widespread distribution network make it a leading player in the industry

      Company History

      Jamjoom Pharmaceuticals Factory Company was established as a branch of Abdullatif Mohammed Salah Jamjoom and Brothers Company under commercial registration no. 4030106218 dated 16/04/1415H (corresponding to 22/09/1994G) issued in Jeddah, KSA. On 12/09/1425H (corresponding to 26/10/2004G), the branch of Abdullatif Mohammed Salah Jamjoom and Brothers Company was converted into a limited liability company under the name of Jamjoom Pharmaceuticals Factory Company Limited under commercial registration no. 4030154596 dated 18/02/1426H (corresponding to 28/03/2005G) with a capital of twenty million Saudi Riyals (SAR 20,000,000). On 17/11/1428H (corresponding to 27/11/2007G), the General Assembly approved an increase of the Company''s capital from twenty million Saudi Riyals (SAR 20,000,000) to sixty million Saudi Riyals (SAR 60,000,000) divided into sixty thousand (60,000) cash shares of equal value of one thousand Saudi Riyals (SAR 1,000) per share, through the capitalization of forty million Saudi Riyals (SAR 40,000,000) from the retained earnings account. On 09/06/1433H (corresponding to 30/04/2012G), the General Assembly approved an increase of the Company''s capital from sixty million Saudi Riyals (SAR 60,000,000) to one hundred million Saudi Riyals (SAR 100,000,000) , divided into one hundred thousand (100,000) cash shares of equal value of one thousand Saudi Riyals (SAR 1,000) per share, through the capitalization of forty million Saudi Riyals (SAR 40,000,000) from the retained earnings account. On 09/11/1434H, (corresponding to 21/01/2013G), the Company was converted from a limited liability company to a (closed) joint-stock company pursuant to a ministerial resolution no. 202/s, dated 19/08/1435H (corresponding to 17/06/2014G) approving the publication of the Company''s conversion. Upon conversion, the Company''s share capital was one hundred million Saudi Riyals (SAR 100,000,000), divided into ten million (10,000,000) Shares with a fully paid-up nominal value of SAR 10 per share. On 18/12/1443H (corresponding to 17/07/2022G), the General Assembly approved an increase of the Company''s capital from one hundred million Saudi Riyals (SAR 100,000,000) to seven hundred million Saudi Riyals (SAR 700,000,000), divided into seventy million (70,000,000) Shares with a fully-paid up nominal value of SAR 10 consisting of ten million ordinary shares paid in-kind and sixty million (60,000,000) ordinary shares paid in cash, per Share through the capitalization of six hundred million Saudi Riyals (SAR 600,000,000) from the retained earnings account.

      Company Bylaws

      Click here

      Equity Profile

      • Authorized Capital (SAR) 700,000,000
      • Issued Shares 70,000,000
      • Paid Capital (SAR) 700,000,000
      • Par Value/Share 10
      • Paid Up Value/Share 10

      Last Update :2023-06-20

      Investment limits

      There are no investment limits on the company's shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on Company's bylaw and the issued Instructions by related regulators and supervisory authorities.

       

      • Company Details
      • BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION

      • Date Established

        1994/09/22

      • Financial Year End

        31/12

      • Listing Date

        2023/06/20

      • External Auditors

        [KPMG Professional Services]

      • ISIN CODE

        SA15QGU1UNH6

      • Number of Employees

        1241

      • Chairman

        Mahmoud Yousuf Mohammed Salah Jamjoom
        Non - Executive

        Mahmoud Yousuf Mohammed Salah Jamjoom
        • BD Session Start
          2022-06-19
          Designation
          Chairman
        • BD Session End
          2025-06-18
          Classification
          Non - Executive
        • Qualification
          Bachelor's Degree in Science from Michigan State University, in East Lansing Michigan, United States, 1985G.
        Companies Membership
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2021-01-01
        • Memebrship Character
          Member of the Executive Committee at the Company
          End Date
          2024-01-01
        • Memebrship Name
          Jamjoom New Medical Care
          Start Date
          2019-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          -

      • Board of Directors

        Ahmed Yousuf Mohammed Salah Jamjoom Executive

        Ahmed Yousuf Mohammed Salah Jamjoom
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Executive
        • Qualification
          Master's degree in pharmacy, from Ibn Sina Medical College, in Jeddah, The Kingdom, 2010G. Mini Master of Business Administration degree in Pharma and Biotech Industry from Management Centre Europe, Brussels, Belgium, 2015. Certificate in Global Management, from the European Institute of Business Administration 'INSEAD', France, Ventenbelau, 2019G.
        Companies Membership
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2021-01-01
        • Memebrship Character
          Member of the Executive Committee at the Company
          End Date
          2024-01-01
        • Memebrship Name
          Abdullatif Mohammed Salah Jamjoom and Brothers Company
          Start Date
          2014-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          -
        • Memebrship Name
          SHIFT Inc.
          Start Date
          2017-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          -
        • Memebrship Name
          SHIFT Inc.
          Start Date
          2020-01-01
        • Memebrship Character
          Member of the Audit Committee
          End Date
          -
        • Memebrship Name
          Madinah Newspapers and Printing
          Start Date
          2017-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          2022-12-31

        Yousuf Mohammed Salah Abdulaziz Jamjoom Non - Executive

        Yousuf Mohammed Salah Abdulaziz Jamjoom
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Non - Executive
        • Qualification
          Diploma degree in Commerce from the College of Leeds, in Leeds, United Kingdom, 1947G
        Companies Membership
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2013-12-31
        • Memebrship Character
          Chairman of the Board of Directors
          End Date
          2022-06-19
        • Memebrship Name
          Jamjoom New Medical Care
          Start Date
          2019-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          -
        • Memebrship Name
          Abdullatif Mohammed Salah Jamjoom and Brothers Company
          Start Date
          1965-01-01
        • Memebrship Character
          Chairman of the Board of Directors
          End Date
          2021-12-31

        Mohammed Yousuf Mohammed Salah Jamjoom Non - Executive

        Mohammed Yousuf Mohammed Salah Jamjoom
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Non - Executive
        • Qualification
          Bachelor's degree in Medicine and Surgery from King Abdulaziz University, The Kingdom, 1983G. Fellowship in Orthopaedic Surgery from the Royal College of Physicians of Canada, Ottawa, Canada, 1993G
        Companies Membership
        • Memebrship Name
          Jamjoom Medicine Store
          Start Date
          2021-01-01
        • Memebrship Character
          Member of the Executive Committee
          End Date
          -
        • Memebrship Name
          Jamjoom New Medical Care
          Start Date
          2019-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          -

        Alaa Yousuf Mohammed Salah Jamjoom Non - Executive

        Alaa Yousuf Mohammed Salah Jamjoom
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Non - Executive
        • Qualification
          Bachelor's Degree in Computer and Statistics from King Abdulaziz University, in Jeddah, The Kingdom, 2005G. Master's Degree in Executive Business Administration from King Abdulaziz University, in Jeddah, The Kingdom, 2008G
        Companies Membership
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          -
        • Memebrship Character
          Member of the Nomination and Remuneration Committee
          End Date
          -

        Faris Ibrahim Abdullah Al Ghannam Independent

        Faris Ibrahim Abdullah Al Ghannam
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Independent
        • Qualification
          Bachelor's Degree in Computer Science from Prince Sultan University, The Kingdom, 2005G. Master's Degree in Business Administration from University of Rice, United States, 2011G
        Companies Membership
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2022-01-01
        • Memebrship Character
          Chairman of the Audit Committee
          End Date
          -
        • Memebrship Name
          Prince Sultan University, The Kingdom
          Start Date
          2022-01-01
        • Memebrship Character
          Member of the Advisory Committee for the Finance Program
          End Date
          -

        Noor Ahmed Kather Pasha Sheriff Non - Executive

        Noor Ahmed Kather Pasha Sheriff
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Non - Executive
        • Qualification
          Bachelor's Degree in Science from Bangalore University, India, 1966G. Bachelor's Degree in Law from Bangalore University, India, 1968G
        Companies Membership
        • Memebrship Name
          Allergan-Primal, India
          Start Date
          1994-01-01
        • Memebrship Character
          Member of the Board of directors
          End Date
          1996-12-31
        • Memebrship Name
          Hydron International, India
          Start Date
          1982-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          1989-12-31

        Michel Marcel Jean-Marie Le Bars Independent

        Michel Marcel Jean-Marie Le Bars
        • BD Session Start
          2022-06-19
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Independent
        • Qualification
          Certificate in Mechanical Engineering (equivalent to a Master's Degree) from the University of Compiegne for Technology, in Compiegne, France, 1994G. Certificate in Petroleum Engineering (drilling and reservoir management) from ENS Petroleum & Engines at the French Institute of Petroleum, in Rueil-Malmaison, in Paris, France, 1995G. Master Degree in Business Administration from Higher Education School of Business in Paris (HEC), France, 2005G. Certificate in Digital Business Strategy from Massachusetts Institute of Technology, in Cambridge, Massachusetts, United States, 2019G.
        Companies Membership
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2022-01-01
        • Memebrship Character
          Chairman of the Executive Committee
          End Date
          -
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2022-01-01
        • Memebrship Character
          Chairman of the Nomination and Remuneration
          End Date
          -
        • Memebrship Name
          LeBars Partners GmbH
          Start Date
          2019-01-01
        • Memebrship Character
          Owner and Managing Director
          End Date
          -

        Georges P. Schorderet Independent

        Georges P. Schorderet
        • BD Session Start
          2023-07-04
          Designation
          Board of Directors
        • BD Session End
          2025-06-18
          Classification
          Independent
        • Qualification
          Master of Business Administration (MBA), IMI International Management Institute, Geneva, Switzerland, 1983. Swiss Certified Public Accountant and Controller, 1985.
        Companies Membership
        • Memebrship Name
          SAPIN Saudi Arabian Packaging Company WLL, Dammam, Saudi Arabia
          Start Date
          2021-01-01
        • Memebrship Character
          Member of the Board of directors
          End Date
          -
        • Memebrship Name
          Sultan Holding, Riyadh, Saudi Arabia
          Start Date
          2021-01-01
        • Memebrship Character
          Member of the Board of directors
          End Date
          -
        • Memebrship Name
          Helvetican Group AG, 6072 Sachseln, Switzerland
          Start Date
          2021-04-01
        • Memebrship Character
          Member of the Board of directors
          End Date
          -
        • Memebrship Name
          SBASA - Swiss Business Association Saudi Arabia
          Start Date
          2021-10-01
        • Memebrship Character
          Chairman
          End Date
          -
        • Memebrship Name
          Global Steel Dust Gulf, Dammam, Saudi Arabia
          Start Date
          2021-09-01
        • Memebrship Character
          Member of the Board of directors
          End Date
          -

      • Senior Executives

        Tarek Youssef Hosni CEO

        Tarek Youssef Hosni
        • BD Session Start
          -
          Designation
          Senior Executives
        • BD Session End
          -
          Classification
          CEO
        • Qualification
          Bachelor's degree in Pharmacy from Alexandria University, Egypt, 1984G. Master's Degree in Business Administration from Bradford University, United Kingdom, 1997G.
        Companies Membership
        • Memebrship Name
          Ultra Group Company
          Start Date
          2022-01-01
        • Memebrship Character
          Member of the Board of Directors
          End Date
          -
        • Memebrship Name
          Jamjoom Pharmaceuticals Factory Company
          Start Date
          2021-01-01
        • Memebrship Character
          Member of the Executive Committee
          End Date
          -

        Anwer Mohiuddin CFO

      Anwer Mohiuddin
      • BD Session Start
        -
        Designation
        Senior Executives
      • BD Session End
        -
        Classification
        CFO
      • Qualification
        Bachelor's Degree of Commerce from University of Karachi, Pakistan, 1985G. Master's Degree of Economics from University of Karachi, Pakistan, 1989G. Master's Degree of Business Administration with a Major in Marketing form Cardiff University, United Kingdom, 2019G Associate Member of Institute of Cost and Management Accountants of Pakistan (ACMA), Pakistan, 1994.

      Investor Relations

      Contact Name:

      Muhammad Bin Khalid Khan

      Company Address:

      P.O. Box # 6267, Jeddah-21442, Kingdom of Saudi Arabia

      Contact Details:

      Telephone: +966 12 614 0099
      Fax : +966 12 614 0088
      Email : IR@Jamjoompharma.com

      Company Website:

      https://www.jamjoompharma.com/


      Name Of Subsidiary Percentage Of Property Main Business Location Of Operation Country Of Operation
      Al-Jamjoom Pharma for Pharmaceutical Industries 100.00% Establishing and operating a factory for the manufacture of human and veterinary medicines, medical preparations, and packaging requirements of all kinds, as well as manufacturing for third parties and by third parties. Egypt Egypt
      Add To Watchlist
      In your Watchlist
      Add To Watchlist

      The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.